{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:26:33Z","timestamp":1787750793040,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63\u20130.99), sinus node dysfunction (RR 0.43, 95% CI 0.19\u20131.00), acute myocardial infarction (RR 0.72, 95% CI 0.60\u20130.85), and angina pectoris (RR 0.77, 95% CI 0.61\u20130.98). Subgroup analyses revealed greater efficacy in patients over 60\u00a0years old and those treated for more than 52\u00a0weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Semaglutide reduces the risk of AF, sinus node dysfunction, acute myocardial infarction, and angina pectoris in patients with overweight or obesity. However, its effects on other arrhythmic, CV, and renal outcomes remain uncertain.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40001-025-03124-y","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T02:45:12Z","timestamp":1756781112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5352-4506","authenticated-orcid":false,"given":"Rui","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5953-5016","authenticated-orcid":false,"given":"Liming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6523-7488","authenticated-orcid":false,"given":"Huishan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"issue":"1","key":"3124_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ecl.2024.10.005","volume":"54","author":"H Lee","year":"2025","unstructured":"Lee H, Rhee TM, Choi JM, et al. The close link between obesity and cardiovascular disease: current insights and remaining challenges. Endocrinol Metab Clin North Am. 2025;54(1):175\u201392.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"3124_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16247","author":"T Forst","year":"2025","unstructured":"Forst T, De Block C, Del Prato S, et al. Novel pharmacotherapies for weight loss: understanding the role of incretins to enable weight loss and improved health outcomes. Diabetes Obes Metab. 2025. https:\/\/doi.org\/10.1111\/dom.16247.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"3124_CR3","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.trsl.2014.03.010","volume":"164","author":"E Jahangir","year":"2014","unstructured":"Jahangir E, De Schutter A, Lavie CJ. The relationship between obesity and coronary artery disease. Transl Res. 2014;164(4):336\u201344.","journal-title":"Transl Res"},{"key":"3124_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pcad.2023.05.003","volume":"78","author":"EK Aryee","year":"2023","unstructured":"Aryee EK, Ozkan B, Ndumele CE. Heart failure and obesity: the latest pandemic. Prog Cardiovasc Dis. 2023;78:43\u20138.","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"3124_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40519-020-00876-w","volume":"26","author":"S Forlivesi","year":"2021","unstructured":"Forlivesi S, Cappellari M, Bonetti B. Obesity paradox and stroke: a narrative review. Eat Weight Disord. 2021;26(2):417\u201323.","journal-title":"Eat Weight Disord"},{"key":"3124_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2025.01.021","author":"A Moiz","year":"2025","unstructured":"Moiz A, Filion KB, Tsoukas MA, et al. Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. Am J Med. 2025. https:\/\/doi.org\/10.1016\/j.amjmed.2025.01.021.","journal-title":"Am J Med"},{"issue":"10456","key":"3124_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949\u201361.","journal-title":"Lancet"},{"issue":"8","key":"3124_CR8","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.clnu.2024.06.034","volume":"43","author":"O Anyiam","year":"2024","unstructured":"Anyiam O, Phillips B, Quinn K, et al. Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus. Clin Nutr. 2024;43(8):1907\u201313.","journal-title":"Clin Nutr"},{"issue":"9","key":"3124_CR9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"key":"3124_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"3124_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"3124_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","volume":"45","author":"R DerSimonian","year":"2015","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45:139\u201345.","journal-title":"Contemp Clin Trials"},{"issue":"14","key":"3124_CR13","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"issue":"14","key":"3124_CR14","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403\u201313.","journal-title":"JAMA"},{"issue":"11","key":"3124_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity\u2013\u2013(STEP 1). N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"10","key":"3124_CR16","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083\u201391.","journal-title":"Nat Med"},{"issue":"3","key":"3124_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193\u2013206.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"3124_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138\u201350.","journal-title":"JAMA"},{"issue":"12","key":"3124_CR19","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"24","key":"3124_CR20","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes\u2013SELECT. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"17","key":"3124_CR21","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391(17):1573\u201383.","journal-title":"N Engl J Med"},{"issue":"9","key":"3124_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","volume":"12","author":"BM McGowan","year":"2024","unstructured":"McGowan BM, Bruun JM, Capehorn M, et al. Efficacy and safety of once-weekly semaglutide 2\u00b74 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 2024;12(9):631\u201342.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"3124_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032277","volume":"13","author":"R Sha","year":"2024","unstructured":"Sha R, Baines O, Hayes A, et al. Impact of obesity on atrial fibrillation pathogenesis and treatment options. J Am Heart Assoc. 2024;13(1):e032277.","journal-title":"J Am Heart Assoc"},{"key":"3124_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231222367","volume":"15","author":"SH Alharbi","year":"2024","unstructured":"Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024;15:20420188231222367.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"3124_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071945","author":"MP Navodnik","year":"2023","unstructured":"Navodnik MP, Jane\u017e A, \u017duran I. The effect of additional treatment with Empagliflozin or Semaglutide on endothelial function and arterial stiffness in subjects with type 1 diabetes mellitus-ENDIS study. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15071945.","journal-title":"Pharmaceutics"},{"key":"3124_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106320","volume":"182","author":"G Bendotti","year":"2022","unstructured":"Bendotti G, Montefusco L, Lunati ME, et al. The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol Res. 2022;182:106320.","journal-title":"Pharmacol Res"},{"issue":"19","key":"3124_CR27","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1001\/jama.2023.2438","volume":"329","author":"M Suran","year":"2023","unstructured":"Suran M. As Ozempic\u2019s popularity soars, here\u2019s what to know about semaglutide and weight loss. JAMA. 2023;329(19):1627\u20139.","journal-title":"JAMA"},{"key":"3124_CR28","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2021.5052","author":"L Wang","year":"2021","unstructured":"Wang L, Ding J, Zhu C, et al. Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazole-kindled mice. Int J Mol Med. 2021. https:\/\/doi.org\/10.3892\/ijmm.2021.5052.","journal-title":"Int J Mol Med"},{"key":"3124_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065714","author":"I Reppo","year":"2023","unstructured":"Reppo I, Jakobson M, Volke V. Effects of semaglutide and empagliflozin on inflammatory markers in patients with type 2 diabetes. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24065714.","journal-title":"Int J Mol Sci"},{"key":"3124_CR30","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.2147\/DDDT.S484531","volume":"18","author":"M Liu","year":"2024","unstructured":"Liu M, Guo S, Li X, et al. Semaglutide alleviates ovary inflammation via the AMPK\/SIRT1\/NF-\u03baB signaling pathway in polycystic ovary syndrome mice. Drug Des Dev Ther. 2024;18:3925\u201338.","journal-title":"Drug Des Dev Ther"},{"key":"3124_CR31","doi-asserted-by":"publisher","first-page":"1394506","DOI":"10.3389\/fendo.2024.1394506","volume":"15","author":"P Pantanetti","year":"2024","unstructured":"Pantanetti P, Cangelosi G, Alberti S, et al. Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice. Front Endocrinol. 2024;15:1394506.","journal-title":"Front Endocrinol"},{"issue":"8","key":"3124_CR32","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/dom.14039","volume":"22","author":"E J\u00f3dar","year":"2020","unstructured":"J\u00f3dar E, Michelsen M, Polonsky W, et al. Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6). Diabetes Obes Metab. 2020;22(8):1339\u201347.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"3124_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/dom.13553","volume":"21","author":"SC Bain","year":"2019","unstructured":"Bain SC, Mosenzon O, Arechavaleta R, et al. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes Obes Metab. 2019;21(3):499\u2013508.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"3124_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"19","key":"3124_CR35","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"key":"3124_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645563","volume":"12","author":"MM Smits","year":"2021","unstructured":"Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol. 2021;12:645563.","journal-title":"Front Endocrinol"},{"issue":"9","key":"3124_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13792","volume":"25","author":"S Kommu","year":"2024","unstructured":"Kommu S, Berg RL. Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2024;25(9):e13792.","journal-title":"Obes Rev"},{"issue":"3","key":"3124_CR38","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/dom.15386","volume":"26","author":"W Qin","year":"2024","unstructured":"Qin W, Yang J, Deng C, et al. Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: an updated systematic review and meta-analysis including the 2-year STEP 5 trial. Diabetes Obes Metab. 2024;26(3):911\u201323.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"3124_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14292","volume":"54","author":"A Saglietto","year":"2024","unstructured":"Saglietto A, Falasconi G, Penela D, et al. Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: a systematic review and meta-analysis. Eur J Clin Invest. 2024;54(12):e14292.","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"3124_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2024.103067","volume":"18","author":"HD Zhang","year":"2024","unstructured":"Zhang HD, Ding L, Liu K, et al. Semaglutide for the prevention of atrial fibrillation: a systematic review and meta-analysis. Diabetes Metab Syndr. 2024;18(6):103067.","journal-title":"Diabetes Metab Syndr"},{"key":"3124_CR41","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.amjcard.2022.04.030","volume":"175","author":"D Patoulias","year":"2022","unstructured":"Patoulias D, Papadopoulos C, Kassimis G, et al. Meta-analysis assessing the cardiovascular safety of semaglutide for the treatment of overweight or obesity. Am J Cardiol. 2022;175:182\u20134.","journal-title":"Am J Cardiol"},{"issue":"10","key":"3124_CR42","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03124-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03124-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03124-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:13:27Z","timestamp":1757477607000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-03124-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3124"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03124-y","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"835"}}